Mr. Frank Gleeson reports

SATELLOS BIOSCIENCE ANNOUNCES APPOINTMENT OF CHIEF MEDICAL OFFICER

Satellos Bioscience Inc. has appointed Alan K. Jacobs, MD, as chief medical officer (CMO) of the company, effective June 7, 2023.

"Dr. Jacobs is an accomplished and experienced clinical development professional with an extensive and impressive track record in both early- and late-stage therapeutic development in the neuroscience and rare disease spaces," says Frank Gleeson, chief executive officer, Satellos Bioscience. "We are delighted to have Dr. Jacobs's clinical leadership on the Satellos team where he will play a lead role in planning and executing clinical trials to advance our novel medicines commencing with Duchenne muscular dystrophy."

Dr. Jacobs joins Satellos from Boston Pharmaceuticals, where as vice-president, clinical development, neuroscience, he oversaw early- and late-stage development programs, led integrated development and biomarker plan creation, created and oversaw clinical trials, and contributed to business development collaborations. Prior to that he held progressively senior leadership roles with Immunovant and Sanofi Genzyme, including strategic co-ordination of multiple successful IND (investigational new drug) submissions and development and execution of phase 2 and 3 clinical trials. Previously, Dr. Jacobs was medical director with both the Ohio Center for Treatment and Research in Multiple Sclerosis and the Center for Neuroscience Research in Dayton, Ohio. He was concurrently a professor of neurology at the Wright State University Boonshoft School of Medicine. Dr. Jacobs is a fellow of the American Academy of Neurology.

"Satellos is doing incredibly important work and is well positioned in its mission to advance the treatment of Duchenne muscular dystrophy and other muscle diseases of high unmet need," says Dr. Jacobs, who has acted as principal investigator on nearly 100 clinical studies in the neurosciences over the course of his career. Continued Dr. Jacobs, "I'm so looking forward to joining such an innovative team and applying my expertise in clinical development to advancing our programs."

In connection with his appointment, the company has granted Dr. Jacobs a total of 1.1 million stock options. Such stock options are exercisable at a price of 56 cents per share for a period of 10 years from the date of grant and vest over a period of four years.

About muscle stem cells and Duchenne muscular dystrophy

Satellos scientific founder Dr. Michael Rudnicki discovered and has demonstrated how muscle stem cells employ a biological process known as stem cell polarity to regulate muscle repair and regeneration throughout life. Dr. Rudnicki has also shown how regulatory defects in stem cell polarity lead to a failure of muscle repair and regeneration in Duchenne muscular dystrophy (DMD), representing a previously unrecognized root cause of DMD. As a result of this continuing inability to produce sufficient numbers of new muscle cells, people with DMD are unable to repair the continuous and accumulating muscle tissue damage. Based on this research, Satellos is advancing a novel small-molecule therapeutic designed to rescue the defect in stem cell polarity and provide a disease-modifying treatment for DMD and other muscular dystrophies.

About Satellos Bioscience Inc.

Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated breakthrough research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, Satellos is building a pipeline of novel therapeutics to correct muscle stem cell polarity and promote the body's innate muscle repair and regeneration process. The company's lead program is an oral, small-molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Satellos is headquartered in Toronto, Ont.

We seek Safe Harbor.